<DOC>
	<DOCNO>NCT02581488</DOCNO>
	<brief_summary>This study design test hypothesis daily treatment diabetic foot ulcer enzymatic debriding agent , SANTYL , 6 week result rapid decrease ulcer area diabetic foot ulcer treat topical treatment contain silver . After meet study criterion , participant randomly assign apply Santyl topical treatment contain silver foot ulcer 6 week . At end 6 week , participant follow additional 4 week examine outcome study treatment .</brief_summary>
	<brief_title>Use Santyl Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Provide write informed consent , consist reading , signing , date informed consent document Investigator , subInvestigator designate study staff member explain study procedure , risk , contact information . 2 . Eighteen ( 18 ) year age old , either sex , race skin type . 3 . Willing able make require study visit . 4 . Able follow instruction perform dress change home caregiver perform dressing change accord protocol . 5 . Willing use appropriate offloading device keep weight foot ulcer . 6 . An ulcer present part plantar surface neuropathic foot hallux 0.5 cm2 10 cm2 inclusive ( measure Screening Visit use ARANZ Silhouette image device ) . The target ulcer duration must ≥ 6 week 52 week ( 12 month ) document subject 's history subject report onset , require debridement . 7 . Adequate arterial blood flow evidence ankle brachial index ( ABI ) &gt; 0.70 ≤ 1.20 . If ABI &gt; 1.2 , perfusion near site ulcer confirm ; foot warm touch palpable pulse . 8 . Separation least 5 cm ( close ulcer edge close ulcer edge ) ≥ 2 ulcer present measure use ARANZ Silhouette image device . 9 . Diabetes mellitus ( Type 1 2 ) require insulin oral/injectable medication control blood glucose level . 10 . Target ulcer infect base clinical assessment . 1 . Contraindications hypersensitivity use clostridial collagenase product contain silver . 2 . Participation another clinical trial within thirty ( 30 ) day Visit 1 , plan participation overlap study . 3 . Bleeding disorder would preclude sharp debridement study . 4 . Active cellulitis target ulcer , lymphangitic streaking , deep tissue abscess , gangrene , infection muscle , tendon , joint bone . 5 . Infection systemic toxicity metabolic instability ( e.g. , fever , chill , tachycardia , hypotension , confusion , vomit , leukocytosis , acidosis , severe hyperglycemia , azotemia ) . 6 . A target ulcer involve underlie tissue tendon , muscle , bone . 7 . Diagnosis chronic granulomatous disease , leukocyte adhesion defect , severe neutropenia . 8 . Current treatment ( time Screening Visit ) following : Systemic corticosteroid . If corticosteroid treatment ≥ 10 day , must 1 week interval discontinuation screening . Immunosuppressive agent Chemotherapeutic agent Antiviral agent Systemic antibiotic therapy ( reason ) topical antibiotic treatment target ulcer 9 . Treatment target ulcer bioactive therapy within 1 month screening : Plateletderived growth factor ( e.g. , Regranex® ) Living skin equivalent ( e.g. , Apligraf® ) Dermal substitute ( e.g. , Dermagraft® , Integra® , Oasis® , etc . ) Amniotic membrane product ( e.g. , EpiFix® , Grafix® , etc . ) 10 . Prior treatment target ulcer length time clostridial collagenase ointment ( SANTYL® ) . 11 . Radiation therapy target low extremity within 30 day prior screen . 12 . Medical physical condition , opinion Investigator , would preclude safe subject participation study . 13 . Blood count blood chemistry value follow : Alanine aminotransferase ( ALT ) &gt; 3x upper limit normal Aspartate aminotransferase ( AST ) &gt; 3x upper limit normal Gamma Glutamyl Transferase ( GGT ) &gt; 2.5x upper limit normal Serum albumin &lt; 2.0 g/dL • Prealbumin level &lt; 10 mg/dL Alkaline phosphatase &gt; 500 U/L • Serum total bilirubin &gt; 3.0 mg/dL Serum BUN &gt; 75 mg/dL • Serum creatinine &gt; 4.5 mg/dL HbA1c &gt; 12 % • Hemoglobin ( Hgb ) &lt; 8.0 g/dL WBC &lt; 2.0 x 109/L • Absolute neutrophil count &lt; 1.0 x 109/L Platelet count &lt; 50 x 109/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>diabetic foot ulcer</keyword>
	<keyword>foot sore</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>neuropathy</keyword>
	<keyword>DFU</keyword>
</DOC>